Health Care | Pharmaceuticals, Biotechnology & Life Sciences | Biotechnology
NASDAQ | Common Stock
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally.
Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.
The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage.
Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.
As of June 11, 2024, Deciphera Pharmaceuticals, Inc. operates as a subsidiary of Ono Pharmaceutical Co., Ltd.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jun 20, 24 | -0.52 Increased by +13.33% | -0.55 Increased by +5.45% |
| Feb 6, 24 | -0.54 Increased by +10.00% | -0.58 Increased by +6.90% |
| Oct 30, 23 | -0.58 Decreased by -5.45% | -0.61 Increased by +4.92% |
| Aug 9, 23 | -0.57 Increased by +5.00% | -0.62 Increased by +8.06% |
| May 3, 23 | -0.60 Increased by +25.00% | -0.59 Decreased by -1.69% |
| Feb 7, 23 | -0.60 Increased by +60.26% | -0.56 Decreased by -7.14% |
| Nov 3, 22 | -0.55 Increased by +59.85% | -0.58 Increased by +5.17% |
| Aug 4, 22 | -0.60 Increased by +50.41% | -0.66 Increased by +9.09% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 45.00 M Increased by +34.55% | -45.08 M Increased by +9.12% | Decreased by -100.19% Increased by +32.46% |
| Dec 31, 23 | 48.29 M Increased by +32.88% | -47.19 M Decreased by -2.73% | Decreased by -97.71% Increased by +22.69% |
| Sep 30, 23 | 43.31 M Increased by +20.40% | -49.58 M Decreased by -25.95% | Decreased by -114.47% Decreased by -4.61% |
| Jun 30, 23 | 38.30 M Increased by +17.88% | -48.56 M Decreased by -16.72% | Decreased by -126.78% Increased by +0.99% |
| Mar 31, 23 | 33.45 M Increased by +14.45% | -49.61 M Decreased by -7.59% | Decreased by -148.33% Increased by +5.99% |
| Dec 31, 22 | 36.34 M Increased by +50.19% | -45.94 M Increased by +48.03% | Decreased by -126.39% Increased by +65.40% |
| Sep 30, 22 | 35.97 M Increased by +54.93% | -39.37 M Increased by +50.69% | Decreased by -109.43% Increased by +68.17% |
| Jun 30, 22 | 32.49 M Increased by +37.84% | -41.61 M Increased by +40.93% | Decreased by -128.05% Increased by +57.14% |